Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Mycophenolate Mofetil Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,676Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BPI's Generic Mycophenolate Mofetil Hydrochloride Receives Approval in the U.S.
    BPI's Generic Mycophenolate Mofetil Hydrochloride Receives Approval in the U.S.

    01 Jun 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214283

    FDA
    01 Jun 2023
    Share Share
    Steriscience's Generic Mycophenolate Mofetil Hydrochloride Receives Approval in the U.S.
    Steriscience's Generic Mycophenolate Mofetil Hydrochloride Receives Approval in the U.S.

    23 Dec 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216390

    FDA
    23 Dec 2022
    Share Share
    Novartis to pay $390 million in U.S. settlement over pharmacy kickbacks
    Novartis to pay $390 million in U.S. settlement over pharmacy kickbacks

    21 Nov 2015

    // Sarah N. Lynch REUTERS

    http://www.reuters.com/article/2015/11/20/us-novartis-pharmacies-kickbacks-idUSKCN0T92MR20151120?rpc=401#cf1zEqDuzgY1HpGE.97

    Sarah N. Lynch REUTERS
    21 Nov 2015
    Share Share
    CellCept,MYFORTIC-Risk of Teratogenicity in Mycophenolate-Containing Products
    CellCept,MYFORTIC-Risk of Teratogenicity in Mycophenolate-Containing Products

    12 Jan 2015

    // HEALTH CANADA

    http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/56690a-eng.php

    HEALTH CANADA
    12 Jan 2015
    Share Share